ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

China · Delayed Price · Currency is CNY

18.56

+0.76 (4.27%)

Sep 30, 2026, 3:00 PM CST

Market Cap	4.09B -33.6%
Revenue (ttm)	911.15M +53.2%
Net Income	204.16M +74.2%
EPS	0.93 +71.8%
Shares Out	220.34M
PE Ratio	20.06
Forward PE	18.69
Dividend	0.25 (1.35%)
Ex-Dividend Date	Jun 5, 2026

Volume	11,373,974
Open	18.12
Previous Close	17.80
Day's Range	17.82 - 18.90
52-Week Range	17.70 - 33.21
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. It provides semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu Sh... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2001

Employees 1,833

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688117

Full Company Profile

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.46 million, an increase of 62.57% compared to the previous year's 456.07 million. Earnings were 157.92 million, an increase of 215.70%.

Financial Statements